Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Magni

Showing results (11-20 of 235) with videos related to

Pageof 24
Sort By:
Clinical Pharmacokinetics|July 2, 2017
Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New DrugsElisa Borella, Italo Poggesi, Paolo Magni
Nutrients|December 23, 2022
Special Issue: Nutraceutical Approaches to Cardiovascular and Metabolic Diseases: Evidence and OpportunitiesPaolo Magni, Andrea Baragetti, Andrea Poli
The AAPS Journal|June 17, 2016
Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in MiceGiulia Lestini, France Mentré, Paolo Magni
Vitamins and Hormones|September 29, 2012
Adiponectin interactions in bone and cartilage biology and diseaseMassimiliano Ruscica, Liliana Steffani, Paolo Magni
Nutrients|March 12, 2022
Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do Not Tell, Yet)Manuela Casula, Alberico Luigi Catapano, Paolo Magni
International Journal of Molecular Sciences|June 27, 2020
Multifactorial Activation of NLRP3 Inflammasome: Relevance for a Precision Approach to Atherosclerotic Cardiovascular Risk and DiseaseAndrea Baragetti, Alberico Luigi Catapano, Paolo Magni
Oncotarget|July 15, 2021
A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in <i>in vivo</i> xenograft studiesElena Maria Tosca, Maurizio Rocchetti, Paolo Magni
Mechanisms of Ageing and Development|March 12, 2021
Inflammaging and neurodegenerative diseases: Role of NLRP3 inflammasome activation in brain atherosclerotic vascular diseaseStefania Cicolari, Alberico L Catapano, Paolo Magni
Pharmaceutics|August 10, 2021
Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like MoleculesElena M Tosca, Roberta Bartolucci, Paolo Magni
European Heart Journal|April 12, 2023
Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease researchMiron Sopic, Georgios Kararigas, Yvan Devaux, et al.
Pageof 24

Showing results (11-20 of 235) with videos related to

Sort By:
Pageof 24
Clinical Pharmacokinetics|July 2, 2017
Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New DrugsElisa Borella, Italo Poggesi, Paolo Magni
Nutrients|December 23, 2022
Special Issue: Nutraceutical Approaches to Cardiovascular and Metabolic Diseases: Evidence and OpportunitiesPaolo Magni, Andrea Baragetti, Andrea Poli
The AAPS Journal|June 17, 2016
Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in MiceGiulia Lestini, France Mentré, Paolo Magni
Vitamins and Hormones|September 29, 2012
Adiponectin interactions in bone and cartilage biology and diseaseMassimiliano Ruscica, Liliana Steffani, Paolo Magni
Nutrients|March 12, 2022
Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do Not Tell, Yet)Manuela Casula, Alberico Luigi Catapano, Paolo Magni
International Journal of Molecular Sciences|June 27, 2020
Multifactorial Activation of NLRP3 Inflammasome: Relevance for a Precision Approach to Atherosclerotic Cardiovascular Risk and DiseaseAndrea Baragetti, Alberico Luigi Catapano, Paolo Magni
Oncotarget|July 15, 2021
A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in <i>in vivo</i> xenograft studiesElena Maria Tosca, Maurizio Rocchetti, Paolo Magni
Mechanisms of Ageing and Development|March 12, 2021
Inflammaging and neurodegenerative diseases: Role of NLRP3 inflammasome activation in brain atherosclerotic vascular diseaseStefania Cicolari, Alberico L Catapano, Paolo Magni
Pharmaceutics|August 10, 2021
Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like MoleculesElena M Tosca, Roberta Bartolucci, Paolo Magni
European Heart Journal|April 12, 2023
Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease researchMiron Sopic, Georgios Kararigas, Yvan Devaux, et al.
Pageof 24